AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$DNA

Kelly Jason R sold $463K of DNA

Kelly Jason R (See remarks) sold 45,682 shares of Ginkgo Bioworks Holdings, Inc. (DNA) at $10.14 ($0.46M total) on 2026-10-19.

Original reporting
SEC EDGAR · Kelly Jason R
Published Oct 21, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 9:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$DNA
Bearish
high confidence
Mentioned
$DNA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DNABearishLow
01

Why it matters

The disclosed sale reduces the insider's holding and may be interpreted as a mild negative signal, but the amount is small relative to the company's market cap.

02

Market read

Primary insider sale filing with modest size; limited trading relevance.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed in the filing.

Relevance 4/10Novelty 4/10Timing: post‑filing today

Background

SEC Form 4 filing reporting an insider's open‑market sale of Ginkgo Bioworks shares.

Company-level read

Ticker impact

$DNABearishHigh confidence
Context

Officer Kelly Jason R sold 45,682 shares for $463,352, reducing his stake to 129,065 shares.

Expected impact

likely slight downward pressure as the market prices the insider sell.

Evidence & confidence

Form 4 is a primary source; the sale size is modest but indicates insider confidence level.

Market effects

Sector

Minimal impact on the synthetic biology sector; insider activity is routine.

Regional

No regional effect; the filing is US‑focused.

Global

Low global relevance.

Counterpoint

What could challenge this read

The sale could be unrelated to company fundamentals and may be a routine liquidity move.

Key entities

  • company
    Ginkgo Bioworks Holdings, Inc.

    Synthetic biology company whose ticker is DNA.

  • person
    Kelly Jason R

    Officer and director of Ginkgo Bioworks.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

DNA insider trading history →

Related articles

$DNAMed

Ginkgo Bioworks: 3 Key Takeaways for Long-Term Investors

Ginkgo Bioworks (NYSE:DNA) reported a strategic shift toward commercializing autonomous lab hardware and cloud services during its Q3 2026 earnings call. Key points include selling hardware to biopharma partners, restructuring to reduce cash burn, and AI-driven demand for lab data. The company ended the quarter with $285M in cash and no debt. Novo Nordisk is a notable partner.

finance.yahoo.com
$DNAMed

Ginkgo Bioworks (DNA) Q3 2026 Earnings Call Transcript

Ginkgo Bioworks (DNA) reported Q3 2026 earnings, showing a 44% improvement in net loss from continuing operations to $41M and a 58% improvement in adjusted EBITDA to -$22M. Revenue was $28M, down 6% YoY. The company highlighted cost-cutting efforts, reduced cash burn, and investments in autonomous labs. They ended the quarter with $285M in cash and reaffirmed full-year cash burn guidance of $125M-$150M.

finance.yahoo.com
$DNALow

Ginkgo Bioworks Reports Third Quarter 2026 Results; Signs First Autonomous Lab Sale to a Top-Tier Pharma Company Novo

Ginkgo Bioworks Holdings, Inc. (DNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ginkgo Bioworks Reports Third Quarter 2026 Results; Signs First Autonomous Lab Sale to a Top-Tier Pharma Company Novo Ginkgo provides an update on its third quarter financial results and the growth of its two prevailing offerings built on one autonomous lab platform:

SEC EDGAR 8-K
$DNAMed

A GT investigation examines the funding, government ties and questionable business practices of seven US entities subject to China’s countermeasures

China’s Ministry of Commerce announced countermeasures against seven US entities, including Applied DNA Sciences (now BNB Plus Corp), Stratum Reservoir, Altana Technologies, Responsible Business Alliance, Verite Group, Human Rights in China, and Compliance Testing LLC, citing US sanctions over alleged forced labor in Xinjiang. The article links their roles to cotton traceability testing, AI supply-chain mapping, compliance services, and related government contracts.

globaltimes.cn
$DNAMed

Ginkgo Bioworks Q2 Earnings Call Highlights

Ginkgo Bioworks (NYSE:DNA) reported first-half 2026 cash burn of $93M, down 3% from $96M a year earlier. Management said Q1 cash burn included a $14M Google Cloud payment tied to an amended 2025 commitment that cut future minimums by over $100M and extended the term to six years. Ginkgo expanded its Nebula lab to 105 racks and raised $17M via an ATM.

yahoo.com